Teva presents positive data from Ajovy pediatric study

Teva (NYSE:TEVA) presented positive data from a Phase 3 study of its drug Ajovy in the prevention of episodic migraine in ...
Nasdaq

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic ...

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab ...